Forendo Pharma, a drug development company, has appointed David Colpman to its board of directors.
Colpman, who becomes the group’s non-executive director, brings with him a career of more than 25 years in pharma and biotech business development and strategy.
He said: “I see great opportunities for Forendo, and look forward to working with the experienced team in the company.”
His previous roles include head of global business development at Shire and business development and commercial positions at Glaxo Wellcome – now GlaxoSmithKline – and Novo Nordisk.
Risto Lammintausta, chief executive officer of Forendo Pharma, said: “We are delighted to welcome David with his broad experience in the industry that will be of significant benefit to Forendo.
“His insights and expertise will be very helpful as we continue to evaluate the commercial alternative of our programmes.”